National Institutes of Health
Division of US Department of Health and Human Services
Latest From National Institutes of Health
Though vastly underreported, new cases of Lyme in the US total more than 300,000 a year; its incidence now exceeds infections for far more visible conditions like HIV. A higher profile for Lyme is hobbled by a slow and distorted institutional response, especially among clinicians who disagree on whether Lyme is one disease or a complex constellation of many – much like cancer, but without the commitment.
A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.
Antibiotic incentives, vaccine strategies, drug pricing, patent updates and more hot topics from the Biotechnology Innovation Organization's recent annual conference.
Transparency is an issue that continues to pose reputational challenges for biopharma. A key flashpoint is the disclosure – under open access rules – of clinical trial data in a climate of mounting therapeutic competition. Still, some industry players are pushing the boundaries around open access. Project Data Sphere, a non-profit group backed by the CEO Roundtable on Cancer, is taking advantage of new IT platforms and the rich target potential in discovery science to press for a larger industry consensus around new ways to release high-value data embedded in years of trials, all for the benefit of cancer patients.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.